The invention also provides methods for detecting IRTA-2, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to IRTA-2 with high affinity.